Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
Study Identifier:
ALXN1007-APS-201
ClinicalTrials.gov Identifier:
EudraCT Identifier:
EU CT ID:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Study Details
Medical Condition
- Antiphospholipid (aPL)-Positive
Study Drug
- Biological: Study Drug- ALXN1007
Date
Apr 2014 - Jun 2016
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 75 Years
Requirements Information
Sex
Female & Male
Age
18 - 75 Years
Study Details
Medical Condition
- Antiphospholipid (aPL)-Positive
Study Drug
- Biological: Study Drug- ALXN1007
Date
Apr 2014 - Jun 2016
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 75 Years years
Requirements Information
Protocol Summary
The primary purpose of this study was to evaluate the safety and tolerability of intravenous (IV) ALXN1007 in persistently antiphospholipid (aPL)-positive patients with at least 1 of the following non-criteria manifestations of APS: aPL-nephropathy, skin ulcers and/or thrombocytopenia.
Trial Locations
Location
Status
Location
Hospital for Special Surgery
New York, New York, United States, 10021
Status
N/A
Location
University of Texas Medical Branch
Galveston, Texas, United States, 77555
Status
N/A
Location
O & O Alpan, LLC
Fairfax, Virginia, United States, 22030
Status
N/A
Location
Hospital das Clínicas da Faculdade de Medicina da USP
São Paulo, Sao Paulo, Brazil, 05403-000
Status
N/A
Location
Hôpital Cochin
Paris, France 75679, France, 75679
Status
N/A
Location
Hopital Claude Huriez - CHU Lille
Lille, Nord, France, 59037
Status
N/A
Go to page